The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Conversation with The Cancer LetterCOVID-19 & Cancer

AACR report: COVID-19 created barriers to cancer screening and care, but accelerated research and telemedicine

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The COVID-19 pandemic disrupted cancer screening and treatment and exacerbated health disparities, but also created unexpected opportunities in cancer research and care, a recent report from the American Association for Cancer Research states. 

The AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care addresses the challenges presented by COVID-19, while noting that the pandemic has fueled scientific research and promoted the use of telemedicine.

“I think this report stresses that investment by the National Institute of Health and the National Cancer Institute in knowledge and science reverts into benefits to society. I think that’s the biggest call to action,” Antoni Ribas, AACR past president and chair of the AACR COVID-19 and Cancer Task Force and Report Steering Committee, said to The Cancer Letter. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Alice Tracey
Alice Tracey
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

Saving Western Kenya’s pediatric blood cancer patients
How flow cytometry is changing the diagnostic landscape

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
By Samuel (Tony) Boova, Eda Holl, LaToya Montgomery, Steve Kussick, Nicholas Kigen, Gilbert Olbara, Festus Muigai Njuguna, Terry Vik and Teresa Loile Lotodo
ClinicalTrials & Tribulations

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
By Enrique Velazquez-Villarreal
Sponsored

The long life of a clinical trial
How JCO sustains landmark oncology research

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
By Journal of Clinical Oncology
Byline
Alice Tracey
Alice Tracey
Reporter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account